title: Dual antiplatelet therapy duration and mortality - Authors' reply.
authors.affiliation: Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Harvard Clinical Research Institute, Boston, MA, USA. Electronic address: ryeh@partners.org.
authors.forename: Robert W
authors.initials: RW
authors.lastname: Yeh
authors.affiliation: Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Harvard Clinical Research Institute, Boston, MA, USA.
authors.forename: Sammy
authors.initials: S
authors.lastname: Elmariah
authors.affiliation: Harvard Clinical Research Institute, Boston, MA, USA; Boston University, Boston MA, USA.
authors.forename: Gheorghe
authors.initials: G
authors.lastname: Doros
authors.affiliation: The Lindner Research Center, The Christ Hospital Heart and Vascular Center, Cincinnati, OH, USA.
authors.forename: Dean J
authors.initials: DJ
authors.lastname: Kereiakes
authors.affiliation: Harvard Clinical Research Institute, Boston, MA, USA; Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
authors.forename: Laura
authors.initials: L
authors.lastname: Mauri
mesh_terms: D002318:Cardiovascular Diseases / Q000188:drug therapy*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D058921:Purinergic P2Y Receptor Antagonists / Q000627:therapeutic use*
chemical_list: D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists